Literature DB >> 16886971

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Felipe F Casanueva1, Mark E Molitch, Janet A Schlechte, Roger Abs, Vivien Bonert, Marcello D Bronstein, Thierry Brue, Paolo Cappabianca, Annamaria Colao, Rudolf Fahlbusch, Hugo Fideleff, Moshe Hadani, Paul Kelly, David Kleinberg, Edward Laws, Josef Marek, Maurice Scanlon, Luis G Sobrinho, John A H Wass, Andrea Giustina.   

Abstract

In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886971     DOI: 10.1111/j.1365-2265.2006.02562.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  155 in total

1.  Editorial: is macroprolactinemia just a diagnostic pitfall?

Authors:  Marcello D Bronstein
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

2.  Ectopic posterior pituitary causing hyperprolactinemia.

Authors:  D Iacovazzo; F Lugli; A Giampietro
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

3.  Effect of dopaminergic drug treatment on surgical findings in prolactinomas.

Authors:  Maria Menucci; Alfredo Quiñones-Hinojosa; Peter Burger; Roberto Salvatori
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

4.  Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.

Authors:  Atanaska Elenkova; Iliana Аtanasova; Georgi Кirilov; Еmil Natchev; Ralitza Ivanova; Roussanka Кovatcheva; Silvia Vandeva; Dimitar Tcharaktchiev; Sabina Zacharieva
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

5.  Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Authors:  L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

6.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.

Authors:  Amit Akirov; Yona Greenman; Benjamin Glaser; Irena S'chigol; Yossi Mansiterski; Yoav Eizenberg; Ilana Shraga-Slutzky; Ilan Shimon
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

Review 8.  Double pituitary adenomas.

Authors:  D Iacovazzo; A Bianchi; F Lugli; D Milardi; A Giampietro; E Lucci-Cordisco; F Doglietto; L Lauriola; L De Marinis
Journal:  Endocrine       Date:  2013-01-17       Impact factor: 3.633

9.  Significance of surgical management for cystic prolactinoma.

Authors:  Toshihiro Ogiwara; Tetsuyoshi Horiuchi; Alhusain Nagm; Tetsuya Goto; Kazuhiro Hongo
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

Review 10.  Review of Presentation, Diagnosis and Management of Pituitary Tumours in Pregnancy.

Authors:  Kimberley Lambert; Catherine Williamson
Journal:  Obstet Med       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.